New Drug Reviews

Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus


Am Fam Physician. 2017 Oct 15;96(8):540-542.

Dulaglutide (Trulicity) is one of six marketed glucagon-like peptide-1 (GLP-1) agonists for the treatment of type 2 diabetes mellitus. In addition to diet and exercise, it may be used alone or in combination with other diabetes medications. It lowers blood glucose levels by stimulating synthesis and secretion of insulin and inhibiting secretion of glucagon.1

 Enlarge     Print

DrugDosageDose formCost*

Dulaglutide (Trulicity)

0.75 mg once weekly, increasing to 1.5 mg if needed

0.75-mg/0.5-mL or 1.5-mg/0.5-mL prefilled syringe for subcutaneous injection


*—Estimated retail price of one month's treatment based on information obtained at (accessed September 5, 2017).

DrugDosageDose formCost*

Dulaglutide (Trulicity)

0.75 mg once weekly, increasing to 1.5 mg if needed

0.75-mg/0.5-mL or 1.5-mg/0.5-mL prefilled syringe for subcutaneous injection


*—Estimated retail price of one month's treatment based on information obtained at (accessed September 5, 2017).


Dulaglutide does not appear to increase cardiovascular events or mortality compared with placebo or other therapies for diabetes, including metformin, sitagliptin (Januvia), exenatide (Byetta), and glargine insulin (Lantus). Safety studies have evaluated the use of dulaglutide in patients for one to two years.2 In one study, 376 patients out of 657 receiving dulaglutide completed a two-year follow-up.3 No difference in mortality or cardiovascular events was reported between patients who received dulaglutide and those who did not.

The risk of hypoglycemia (defined as a serum blood glucose level less than 70 mg per dL [3.9 mmol per L]) with dulaglutide alone1,4 or in combination with metformin is about 8% over one year.3 Episodes of severe hypoglycemia (requiring intervention) are less common, occurring in about 0.2% of patients over one to two years.4 In clinical trials, all episodes of severe hypoglycemia with dulaglutide use occurred in the setting of concomitant sulfonylurea or insulin therapy.46 The risk of hypoglycemia with dulaglutide does not appear to be dose dependent.1

One of the biggest concerns about dulaglutide and other GLP-1 agonists from postmarketing reports is the risk of pancreatitis. These products contain labeling recommending against their use in patients with a history of pancreatitis.7 An independent meta-analysis of 55 randomized controlled trials following more than 33,000 patients for six months to four years found the risk of pancreatitis to be 0.1% in patients using any class of medication for type 2 diabetes.8 There was no difference in risk between GLP-1 agonists and other classes.

As with other GLP-1 agonists, there is a theoretical risk of patients developing thyroid C-cell carcinoma, based on rodent studies. These products should not be used in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.7

Dulaglutide is not recommended for use in children. Animal studies suggest a potential risk to the fetus if the medication is used during pregnancy. It has not been evaluated in breastfeeding women.7


Dulaglutide is generally well tolerated. In clinical trials, dropout rates were similar to those with placebo. About 10% of patients will experience nausea, vomiting, abdominal pain, decreased appetite, and diarrhea. These adverse effects are most common during the first two weeks of therapy. Vomiting is the only adverse effect that is significantly increased compared with placebo or metformin monotherapy (number needed to harm = 21).1


Dulaglutide as monotherapy reduces A1C levels by 0.5% to 0.7%. Higher dosages of dulaglutide do not provide a further significant decrease in A1C.9 In combination with metformin, dulaglutide lowers A1C levels by an additional 0.7% to 1.0%.3

All GLP-1 agonists slow gastric emptying and decrease hunger. Weight loss with dulaglutide alone is about 1.1 to 2.3 kg (2.4 to 5.1 lb); in combination with metformin, weight loss will be about 2.6 to 3.3 kg (5.7 to 7.3 lb).4,9 Weight loss is greater with higher dosages of dulaglutide.1,9

No studies have evaluated the effect of dulaglutide on cardiovascular events, morbidity, or mortality in patients with type 2 diabetes.


A one-month supply of dulaglutide costs approximately $712, which is similar to the price of other GLP-1 agonists. In contrast, other glucose-lowering agents used as monotherapy are much less expensive.


Dulaglutide is a once-weekly subcutaneous injection. It comes in a single-dose 0.75-mg/0.5-mL prefilled syringe that should be stored in a refrigerator until use. The recommended starting dosage is 0.75 mg once weekly, increasing to 1.5 mg once weekly if additional glycemic control is needed.

Bottom Line

Dulaglutide is an easy-to-use, once-weekly injectable therapy for the treatment of type 2 diabetes in adults. It produces a modest decrease in A1C levels with only a small risk of severe hypoglycemia. The small average weight loss it induces may be an advantage for some patients. Critically, there is no research showing a mortality or morbidity benefit with dulaglutide. It may be used as adjuvant therapy to metformin, but there are less expensive, equally effective options available when adding a second medication for patients with type 2 diabetes. Liraglutide (Victoza) may be a preferable GLP-1 agonist, given its ability to reduce cardiovascular events.10

Author disclosure: No relevant financial affiliations.

Address correspondence to Emma Pace, MD, at Reprints are not available from the authors.


show all references

1. Zhang L, Zhang M, Zhang Y, Tong N. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep. 2016;6:18904....

2. Ferdinand KC, Botros FT, Atisso CM, Sager PT. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016;15:38.

3. Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849–858.

4. Boustani MA, Pittman I IV, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥ 65 and < 65 years. Diabetes Obes Metab. 2016;18(8):820–828.

5. Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385(9982):2057–2066.

6. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241–2249.

7. DailyMed. Trulicity prescribing information. Accessed April 1, 2017.

8. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ. 2014;348:g2366.

9. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168–2176.

10. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, Contributing Editor.

A collection of STEPS published in AFP is available at



Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


Oct 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article